Wockhardt USA

Wockhardt USA is a subsidiary of Wockhardt Limited, established in 2004, focused on the biotechnology and pharmaceutical industries in the United States. Over the years, it has rapidly expanded its portfolio, now representing more than 20% of Wockhardt Ltd’s global business, with over 220 NDCs spanning more than 75 different product families. With more than 14 years of experience in the US market, Wockhardt USA has received over 110 ANDA approvals to date, demonstrating its commitment to product quality and compliance. The acquisition of Morton Grove Pharmaceuticals in October 2007 further strengthened Wockhardt's presence in the US, expanding its product line to include oral liquid and topical pharmaceuticals. Morton Grove has been a key player since 1995, known for its state-of-the-art 125,000 square foot facility, showcasing Wockhardt's strategic moves to diversify its offerings in the market. Wockhardt USA's trajectory signifies its potential for growth and innovation within the pharmaceutical sector, presenting an attractive opportunity for venture capital investment in a company with a strong track record and a focus on delivering high-quality generic oral solids, liquids, topicals, and injectables to the US market.